Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06105827
Other study ID # NMT16049S
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date October 2, 2016
Est. completion date April 25, 2019

Study information

Verified date October 2023
Source Xintian Pharmaceutical
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Objective: To observe the effect of Ningmitai capsule on ureteral calculi after lithotripsy and evaluate the safety of treatment. Study Design: A multicenter, prospective, randomized, controlled clinical study design was adopted Interventions: control group: Give antibiotics or diclofenac sodium suppository as needed. Ningmitai group: Oral Ningmitai Capsule (produced by Guiyang Xintian Pharmaceutical Co., Ltd.), 0.38 g/capsule, 4 capsules each time, 3 times a day. combination group (Ningmitai plus tamsulosin).: Tamsulosin capsules, 0.2 mg/capsule, one capsule each time, once a day, were taken on the basis of Ningmitai group.


Description:

Sample size: 230


Recruitment information / eligibility

Status Completed
Enrollment 251
Est. completion date April 25, 2019
Est. primary completion date April 25, 2019
Accepts healthy volunteers No
Gender All
Age group 20 Years to 70 Years
Eligibility Inclusion Criteria: 1. Diagnosed as upper urinary calculi by B-ultrasound, kidney and upper bladder (KUB), intravenous urogram (IVU) or computerized tomography (CT) before surgery with the ages between 20 and 70 years. 2. Having ureteral residual fragments post URL and the diameter more than 5mm. 3. The lithotripsy went smoothly with expected outcomes and without any ureteral perforation, mucous exfoliation, kidney or bladder injury, serious bleeding or any other complications. 4. Willing and able to participate in this study and comply with all scheduled visits, treatment plans and complete the clinical observations. Exclusion Criteria: 1. Pregnancy, severe diabetes, or renal insufficiency. 2. Ureteral stricture and lower urinary tract obstruction. 3. Concomitant treatment with a1-receptor antagonists, or Chinese traditional medicines who can be used to relieve stranguria and expel stone, or any other treatment that might interference the efficacy evaluation. 4. Unwilling or unable to comply with the administration regimen described in the protocol, or having an incomplete profile, hence their efficacy and safety couldn't be evaluated. 5. Severe adverse events and need to withdraw from the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Control group
Give antibiotics or diclofenac sodium suppository as needed.
Ningmitai capsule
Oral Ningmitai Capsule (produced by Guiyang Xintian Pharmaceutical Co., Ltd.), 0.38 g/capsule, 4 capsules each time, 3 times a day for 12 Weeks.
Combined group (Ningmitai plus tamsulosin)
Tamsulosin capsules, 0.2 mg/capsule, one capsule each time, once a day, were taken on the basis of Ningmitai group for 12 Weeks.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Xintian Pharmaceutical

Outcome

Type Measure Description Time frame Safety issue
Primary the stone expulsion time, stone-free time The diminishing or vanishing of residual fragment identified by post-surgery B-ultrasound or KUB could suggest a residual fragment expulsion. Evaluation with KUB showing the shadow of calculi disappearing completely followed by a confirmation using CT could suggest a residual fragment clearance. From baseline to 12 weeks of treatment
Secondary the stone expulsion rate and stone-free rate. The diminishing or vanishing of residual fragment identified by post-surgery B-ultrasound or KUB could suggest a residual fragment expulsion. Evaluation with KUB showing the shadow of calculi disappearing completely followed by a confirmation using CT could suggest a residual fragment clearance. From baseline to 12 weeks of treatment
See also
  Status Clinical Trial Phase
Recruiting NCT05100017 - Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure N/A
Recruiting NCT03692715 - Antibiotic Prophylaxis Before Shock Wave Lithotripsy Phase 4
Recruiting NCT01450566 - Intraureteral Lidocaine for Post-Ureteroscopy Pain N/A
Completed NCT00831701 - Medical Expulsive Therapy of Single Distal Ureteral Stones N/A
Completed NCT00177086 - Alfuzosin Hydrochloride to Promote Passage of Distal Ureteral Calculi Phase 3
Completed NCT02577146 - The Predictive Value of Ureteral Jet Assessment With Ultrasound in Patients Presenting With Acute Renal Colic N/A
Completed NCT00517205 - Study on 'The Use of Non-contrast Helical Computerized Tomogram in Predicting Treatment Outcomes of Upper Ureteric Stone by Extracorporeal Shock Wave Lithotripsy Using the Sonolith 4000+ Lithotripter' N/A
Completed NCT03888144 - Study of Ketorolac Versus Opioid for Pain After Endoscopy Phase 4
Not yet recruiting NCT04606758 - Fluoroscopic Guided vs US-guided Percutaneous Nephrolithotripsy for the Treatment of Stone Disease N/A
Not yet recruiting NCT01008267 - Shockwave Lithotripsy (SWL) Under Selective, General Anesthesia. N/A
Completed NCT04069338 - Comparison of Lithotripsy Urolithiasis Machines N/A
Recruiting NCT04069013 - Standard vs Mini-PCNL for the Treatment of Stone Disease N/A
Withdrawn NCT00304317 - Celecoxib (Celebrex) in the Management of Acute Renal Colic Phase 4
Recruiting NCT01167062 - Efficacy of Tamsulosin Oral-controlled Absorption System (OCAS) in the Treatment of Distal Ureteral Stones Phase 4
Completed NCT01144949 - Study of Silodosin to Facilitate Passage of Urinary Stones Phase 2
Terminated NCT03614052 - Tamsulosin as Adjuvant Treatment Prior to Endoscopic Ureterolithotomy Phase 4
Completed NCT03344120 - Symptoms Comparison: Suture-stent vs Conventional Double-J Stents After Ureterorenoscopy. A Prospective Randomized Trial N/A
Completed NCT05153629 - Noninvasive Electrical Stimulator as a Pain Control Treatment Post-ureteroscopy N/A
Recruiting NCT05739812 - The Efficacy and Safety of Chinese Domestic Surgical Robot System in Urological Telesurgery N/A
Completed NCT01542593 - Evaluating Ureteral Length Using Computed Tomography (CT) N/A